الفهرس 
Introduction
Aim of the StudyOnly 14 pages are availabe for public view
 |  | from | 63 |  |  |
| | | from | 63 | | |
Abstract
Upper gastrointestinal cancers include cancer of the oesophagus and stomach. Upper Gastro-Intestinal (GI) cancer is an increasingly common presentation of malignant disease in Western populations.
The incidence varies to a considerable extent within countries, and even within quite small countries. In general it is commoner in the northern parts of countries in the northern hemisphere than in the southern parts, although no such difference is revealed in Norway.
There were limited about frequency and incidence of upper gastrointestinal malignancies in our locality. The current study was performed to determine the pattern of upper gastrointestinal malignancies in Egypt South Institute in period between 2009 and 2014.
It included 202 patients known to have upper gastrointestinal malignancies. Mean age was 52.9 ± 14.5 years. One hundred and nine (52.8%) were males and the same percentage were smokers. Male to female ratio was 1.3.
It was noticed that the most frequent complaint was vomiting that occurred in 84 (38.1.9%) patients followed by dysphagia and epigastric pain presented in 72 (33.3%) and 56 (25.9%) patients respectively. Nausea and anorexia were the least frequent complaint where only five (2.3%) and two (0.9%) patients were complaining of them respectively. History of GERD symptoms presented in 50 (24.7%) patients.
Regarding site of upper GIT malignancies on diagnostic upper endoscopy; stomach was the most frequent site (129 (59.7% patients) where body was the commonest site followed by cardia and antrum (53 (24.5%), 45 (20.8%), 31 (14.4%) patients respectively).
Regarding the microscopic appearance of the upper GIT in our study; carcinoma, adenocarcinoma, squamous cell carcinoma, and non-hodgkin lymphoma presented in 21 (9.7%), 137 (63.4%), 30 (13.9%) and 28 (13%) patients respectively.
Survival analysis showed that gastroesophageal tumor (25 months) had significantly mean survival in comparison to gastric (21 months) and esophageal carcinoma (17 months).